TY - JOUR
T1 - Specific HLA-DRB1 Alleles Associate With Anti-Caspr1 and Anti-CNTN1 Autoantibodies in Autoimmune Nodopathies
AU - Lleixà, Cinta
AU - Pascual-Goñi, Elba
AU - Martín-Aguilar, Lorena
AU - Caballero-Ávila, Marta
AU - Collet-Vidiella, Roger
AU - Tejada-Illa, Clara
AU - Llarch, Paula
AU - Gallardo, Eduard
AU - Boera-Carnicero, Gemma
AU - Calahorro, Verónica
AU - Callegari, Ilaria
AU - Cortese, Andrea
AU - Delmont, Emilien
AU - Devaux, Jerome
AU - Giannotta, Claudia C
AU - Nobile-Orazio, Eduardo
AU - Höftberger, Romana
AU - Sellner, Johann
AU - Herdewyn, Sarah Andrée Annie J
AU - Alejandra, Carvajal
AU - Torné, Laura
AU - Jericó, Ivonne
AU - Rinaldi, Simon
AU - Sommer, Claudia
AU - Doppler, Kathrin
AU - Armangue, Thais
AU - Titulaer, Maarten J
AU - Jacobs, Bart C
AU - Huizinga, Ruth
AU - Wanschitz, Julia V
AU - Ortiz Castellon, Nicolau
AU - Sparasci, Davide
AU - Ripellino, Paolo
AU - Pérez-Pérez, Helena
AU - Horga, Alejandro
AU - Alonso-Jiménez, Alicia
AU - De Winter, Jonathan
AU - Jauregui, Amaia
AU - de la Calle-Martin, Oscar
AU - Martinez-Martinez, Laura
AU - Querol, Luis
N1 - Publisher Copyright:
Copyright © 2026 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
PY - 2026/7/1
Y1 - 2026/7/1
N2 - BACKGROUND AND OBJECTIVES: This study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).METHODS: Forty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the Allele frequencies database.RESULTS: HLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, p = 0.01) and 2.2 (CI = 1.07 to 4.53, p = 0.04), respectively. HLA-DRB1*03:01 alleles appeared in significantly higher proportions in anti-Caspr1+ patients than in CIDP patients and in the general population (64.3% vs 22% vs 24.2%), with an odds ratio of 6.38 (CI = 1.77 to 22.99, p = 0.007) and 5.64 (CI = 1.876 to 16.96, p = 0.002), respectively. In the anti-Caspr1+ group, we included 3 patients presenting with antibodies against both CNTN1 and Caspr1 proteins in the acute phase, in which the anti-CNTN1 antibodies disappeared in the chronic phase.DISCUSSION: HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.
AB - BACKGROUND AND OBJECTIVES: This study describes the human leukocyte antigen (HLA) Class II allele frequencies in patients with anti-CNTN1+ and anti-Caspr1+ autoimmune nodopathy (AN).METHODS: Forty-four AN patients and 50 seronegative CIDP patients from 19 different European hospitals were included in the study. Thirty AN patients had anti-contactin 1 (CNTN1) antibodies, 11 anti-contactin-associated protein 1 (Caspr1) antibodies, and 3 had antibodies against both proteins. HLA-DRB1 was genotyped at the 4-digit allele levels, and the percentage of individuals carrying each allele was compared with that of the general population, obtained from the Allele frequencies database.RESULTS: HLA-DRB1*11 alleles appeared in higher proportions in anti-CNTN1+ patients than in seronegative CIDP patients and in the general population (46.7% vs 18% vs 28.4%), with an odds ratio of 3.99 (CI = 1.44 to 11.03, p = 0.01) and 2.2 (CI = 1.07 to 4.53, p = 0.04), respectively. HLA-DRB1*03:01 alleles appeared in significantly higher proportions in anti-Caspr1+ patients than in CIDP patients and in the general population (64.3% vs 22% vs 24.2%), with an odds ratio of 6.38 (CI = 1.77 to 22.99, p = 0.007) and 5.64 (CI = 1.876 to 16.96, p = 0.002), respectively. In the anti-Caspr1+ group, we included 3 patients presenting with antibodies against both CNTN1 and Caspr1 proteins in the acute phase, in which the anti-CNTN1 antibodies disappeared in the chronic phase.DISCUSSION: HLA-DRB1*11 alleles are associated with the detection of anti-CNTN1 antibodies in AN patients, and HLA-DRB1*03:01 alleles associate with anti-Caspr1 antibodies. In addition, our study suggests that antiparanodal antibodies targeting both Caspr1 and CNTN1 are present in a small number of patients with AN. These data reinforce the idea that these patients represent specific subsets with clinical features and risk factors that differ from seronegative CIDP patients and from other AN patients. However, further studies should address the functional relevance of these associations and their pathophysiologic implications.
KW - Humans
KW - HLA-DRB1 Chains/genetics
KW - Autoantibodies/blood
KW - Female
KW - Middle Aged
KW - Male
KW - Contactin 1/immunology
KW - Adult
KW - Gene Frequency
KW - Aged
KW - Autoimmune Diseases of the Nervous System/genetics
UR - https://www.scopus.com/pages/publications/105043654639
U2 - 10.1212/NXI.0000000000200602
DO - 10.1212/NXI.0000000000200602
M3 - Journal article
C2 - 42335443
SN - 2332-7812
VL - 13
SP - e200602
JO - Neurology: Neuroimmunology and NeuroInflammation
JF - Neurology: Neuroimmunology and NeuroInflammation
IS - 4
M1 - e200602
ER -